The role of entrectinib

Entrectinib is a targeted therapy used to treat certain types of cancer, primarily those carrying the NTRK gene fusion (fusion) or ROS1 gene rearrangement (rearrangement) tumors. The following is the role of entrectinib and its clinical application:

1.Inhibition of NTRK protein and ROS1 protein: Entrectinib is a multi-target inhibitor that mainly acts on NTRK protein and ROS1 protein. When NTRK gene fusion or ROS1 gene rearrangement occurs, the activity of these proteins will be abnormally enhanced, promoting the growth and spread of cancer cells. Entrectinib can prevent the proliferation of cancer cells by inhibiting the activity of these proteins, thereby slowing the growth of tumors.

2.TreatmentNTRKfusion-positive tumors: NTRKGene fusion is a rare but biologically significant genetic variation that can appear in a variety of cancer types, such as lung cancer, breast cancer, and soft tissue sarcoma. Entrectinib is used to treat tumors carrying NTRK gene fusions, including recurrent or metastatic tumors, by targeting the inhibition of the NTRK protein.

3.TreatmentROS1Tumors positive for gene rearrangement:ROS1Gene rearrangement is another type of genetic variation that is rare but appears in some specific types of cancer, such as non-small cell lung cancer. Entrectinib is also used to treat tumors carrying ROS1 gene rearrangements. It can inhibit the activity of ROS1 protein, thereby inhibiting tumor growth.

4.Targeting multiple cancer types: Since NTRKgene fusions and ROS1gene rearrangements can occur in multiple cancer types, entrectinib is considered a cross-tumor therapeutic agent. It has demonstrated potential efficacy in the treatment of a variety of solid tumors and hematological diseases, providing new treatment options for patients with rare tumors or difficult-to-treat cancers.

5.Improve patients’ survival and quality of life: Clinical trial results show that entrectinib shows good efficacy in patients with NTRKfusion or ROS1 rearrangement-positive tumors, can significantly extend the patient’s survival, is generally well tolerated, and can improve the patient’s quality of life.

In general, entrectinib, as a targeted therapy, has shown significant therapeutic effects against tumors with NTRK gene fusions and ROS1 gene rearrangements, providing an important treatment option for these patients.